[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"familial-hypercholesterolaemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:familial-hypercholesterolaemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,80,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100637749","an-observational-study-to-evaluate-treatment-patterns-in-high-very-high-and-extreme-cardiovascular-risk-patients-with-hypercholesterolemia-including-familial-hypercholesterolemia-100637749",false,"NCT07606118","An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia","An Observational Longitudinal Multicenter Prospective Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia, Over a 1-Year Follow- Up","TRAP-HC","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of hypercholesterolemia (including clinical or genetic FH) OR high\u002Fvery high\u002Fextreme CV risk\n* Baseline visit within enrollment window (six months)\n\nExclusion Criteria:\n\n* Significant secondary dyslipidemia (e.g. hypertriglyceridemia)\n* Treatment changes due to non-hypercholesterolemia conditions","ALL","18 Years",{"count":20,"type":21},2500,"ESTIMATED","OBSERVATIONAL","TRAP-HC is a multicenter, observational, longitudinal, prospective study designed to evaluate real-world treatment patterns and lipid-lowering therapy (LLT) management in patients with hypercholesterolemia, including familial hypercholesterolemia (FH), who are at high, very high, or extreme cardiovascular risk. Approximately 2,500 adult patients will be enrolled across up to 15 Italian LIPIGEN network centers and followed for 12 months as part of routine clinical practice.\n\nThe study aims to assess LDL-C goal attainment according to current European guidelines, evaluate changes in lipid profiles over time, and investigate treatment adherence, persistence, and therapeutic modifications in response to clinical needs. Data collected during routine visits will include lipid parameters, cardiovascular history, concomitant therapies, safety outcomes, and patient-reported adherence measures.\n\nBy providing real-world evidence on the management of hypercholesterolemia in high-risk populations, the study seeks to identify current gaps between guideline recommendations and clinical practice and to support optimization of cardiovascular risk reduction strategies.",[25,26,27],"Hypercholesterolaemia","Familial Hypercholesterolaemia","CVD Risk",[29,30,31,32,33,34,35,36,37],"LDL Cholesterol","Lipid-Lowering Therapy","Cardiovascular risk","LDL-C goal attainment","Real-world evidence","Lipid Profil","Adherence to Lipid-Lowering Therapies","Changes in Treatment Regimens","Patient Attitudes and Clinical Practices","NOT_YET_RECRUITING","2026-05-20",{"date":41,"type":42},"2026-05-26","ACTUAL",{"date":44,"type":21},"2026-06-30",{"date":46,"type":21},"2027-12-31",{"name":48,"class":49},"Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":77,"locationsCount":79},"100573236","computerized-decision-support-for-identification-and-management-of-familial-hypercholesterolemia-100573236","NCT06743659","Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia","Alert-Based Computerized Decision Support for Identification and Management of Patients With Familial Hypercholesterolemia (FH-ALERT Trial)","FH-ALERT","Inclusion Criteria:\n\n* ≥ 18 years old\n* seen in the BWH Endocrinology, Cardiovascular Medicine, and Primary Care Clinics\n* Dutch Lipid Clinic Network score of at least 3 points\n\nExclusion Criteria:\n\n* a Familial Hypercholesterolemia diagnosis already documented in the EHR medical history, visit history, or problem list",{"count":59,"type":21},450,"INTERVENTIONAL",[62],"NA","The goal of this clinical trial is to learn if a computer alert can aid clinicians in identifying patients with a genetic type of high cholesterol, called Familial Hypercholesterolemia. The main question it aims to answer is whether the computer alert increases recognition of this high cholesterol disorder.",[26],[66,67,68,69],"Familial Hypercholesterolemia","Computerized Decision Support","Electronic Alerts","High Cholesterol","RECRUITING","2025-09-15",{"date":73,"type":42},"2025-09-18",{"date":75,"type":42},"2025-04-01",{"date":46,"type":21},{"name":78,"class":49},"Brigham and Women's Hospital",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":91,"conditions":92,"keywords":117,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100599630","cardiovascular-risk-in-children-with-chronic-conditions-study-100599630","NCT07086989","Cardiovascular Risk in Children With Chronic Conditions Study","CR3C","Inclusion criteria:\n\n1. Individuals aged between 6 and 25 years;\n2. Diagnosed with a chronic childhood condition\u002Fdisease associated with an increased risk of early cardiovascular disease;\n3. Provided informed consent (if over 18 years old) or had informed consent provided by their legal guardian (if under 18 years old) following appropriate information about the study.\n\nChronic childhood conditions\u002Fdiseases associated with increased risk of early cardiovascular disease are defined according to the 2019 American Heart Association recommendations (https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIR.0000000000000618), as well as other conditions\u002Fdiseases for which at least two large-scale epidemiological studies have demonstrated an increased risk of cardiovascular disease.\n\nExclusion criteria:\n\n1. Severe intellectual and developmental disability;\n2. Decompensated heart failure;\n3. Severe primary immunodeficiency;\n4. Ongoing intravenous chemotherapy;\n5. Infectious diseases posing a public health risk; or\n6. History of regular alcohol or drug use.","6 Years","25 Years",{"count":90,"type":21},300,"Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels. Although experts recognize this elevated risk and recommend close monitoring and early intervention, the underlying mechanisms driving this phenomenon remain poorly understood. At present, no effective interventions specifically target its root causes.\n\nRecent research shows that both large blood vessels (such as the carotid artery) and small vessels (such as those in the retina) can display early signs of damage decades before clinically apparent heart or vascular disease emerges. This accelerated vascular aging can result from multiple factors - including disease-related processes such as persistent inflammation and metabolic disturbances, treatment-related effects such as chemotherapy or long-term steroid use, and lifestyle changes associated with chronic illness, such as reduced physical activity and altered eating habits. However, it is still unclear how these factors influence the development and progression of vascular changes in children as they grow. Importantly, these changes can be monitored through non-invasive methods, offering a unique opportunity to study at-risk patients many years before overt cardiovascular disease develops.\n\nIdentifying these early changes may enable us to detect and track individuals at heightened risk well in advance of clinical disease. This study aims to deepen our understanding of the causes of increased cardiovascular risk in children with chronic conditions and to lay the groundwork for earlier, more targeted prevention strategies.",[93,26,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116],"Kidney Transplant","Type 1 Diabetes Mellitus (T1DM)","Type 2 Diabetes Mellitus (T2DM)","Chronic Kidney Disease","Kawasaki Disease","Liver Transplant","Obesity and Overweight","Hypertension","Coarctation of Aorta","Bone Marrow Transplant","Cancer (Solid Tumors)","Leukemia","Lymphoma","Lipoprotein(a)","Aorta Stenosis","Non Alcoholic Fatty Liver Disease","Dyslipaemia","White Coat Hypertension","Pulmonary Hypertension","Juvenile Idiopahtic Arthritis","Systemic Lupus Erthematosus","Inflammatory Bowel Disease (IBD)","HIV Infection","Transposition of Great Arteries",[118,119,120],"cardiovascular risk","vasculature","children with chronic conditions","2025-08-04",{"date":123,"type":42},"2025-08-08",{"date":75,"type":42},{"date":126,"type":21},"2029-01-31",{"name":128,"class":49},"Semmelweis University",3,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":17,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":79},"100262278","the-spanish-familial-hypercholesterolaemia-cohort-study-100262278","NCT02693548","The Spanish Familial Hypercholesterolaemia Cohort Study","SAFEHEART","Inclusion Criteria:\n\n* Index cases with genetic diagnosis of FH and their relatives over 15 years old with a genetic diagnosis of FH and their first-degree relatives\n\nExclusion Criteria:\n\n* Patient unwillingness",true,"15 Years",{"count":140,"type":21},4141,"SAFEHEART is a large, on-going registry study in molecularly defined patients with heterozygous FH treated in Spain.",[26],[26,144,145],"Prognosis","Cardiovascular disease","2025-02-26",{"date":148,"type":42},"2025-02-28",{"date":150,"type":42},"2004-01",{"date":152,"type":21},"2030-10",{"name":154,"class":49},"Fundación Hipercolesterolemia Familiar"]